NCT07827573
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07827573
Title A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment (kalitERA)
Acronym kalitERA
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Hematology Oncology Salem RECRUITING Salem Oregon 97301 United States Details
Virginia Cancer Institute RECRUITING Richmond Virginia 23229 United States Details
Jewish General Hospital RECRUITING Montreal Quebec H3T 1E2 Canada Details
CHU de Québec - Hôpital du Saint-Sacrement RECRUITING Québec Quebec G1S 4L8 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field